Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Dundee Corporation (DC.A) portfolio holding, TauRx Pharmaceuticals, has raised US$119 million to fund TauRx’s regulatory submissions in the UK, US and Canada
  • Proceeds will also be used to advance development plans for regulatory approval in China
  • President and CEO Jonathan Goodman sat down with Sabrina Cuthbert to discuss the news
  • Dundee Corporation is a Canadian independent holding company with a 3.2 per cent interest in TaxRx Pharmaceuticals
  • Dundee Corporation (DC.A) opened trading at C$1.37

Dundee Corporation (DC.A) portfolio holding, TauRx Pharmaceuticals, has raised US$119 million through a warrant exercise.

The proceeds will fund TauRx’s regulatory submissions in the UK, US and Canada and advance development plans for regulatory approval in China.

President and CEO Jonathan Goodman sat down with Sabrina Cuthbert to discuss the news. “We are extremely pleased to learn that TauRx was successful in its efforts to secure the necessary funding to undergo regulatory submissions of its promising Alzheimer’s treatment in 2023. We wish the company well in these efforts and look forward to its presentation of results of its LUCIDITY trial at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco on November 30th.”

TauRx announcement highlights:

  • TauRx achieved a substantial investment of US$119 million through the exercise of warrants received from the previously announced rights offering.
  • Proceeds will be used to fund regulatory submissions in the UK, US and Canada, and preparation for market availability
  • Shareholder commitment to TauRx represents a significant success story for UK-based life sciences research and development in areas of great unmet medical need
  • TauRx will present the Phase 3 findings at the Clinical Trials on Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco

Dundee holds 1,015,008 shares in TauRx, representing a 3.2 per cent interest in the company.

Dundee Corporation is a Canadian independent holding company. Through its operating subsidiaries, Dundee Corporation is an active investor focused on delivering long-term, sustainable value as a trusted partner in the mining sector with more than 30 years of experience making accretive mining investments.

Dundee Corporation (DC.A) opened trading at C$1.37.


More From The Market Herald
Pharmala Biotech Holdings Inc. - CEO & President, Nick Kadysh.

" PharmAla (CSE:MDMA) named exclusive MDMA supplier to Revive Therapeutics (CSE:RVV)

PharmAla Biotech Holdings (MDMA) has signed an agreement to be Revive Therapeutics’ (RVV) exclusive supplier of clinical-grade MDMA.
The Market Herald Video

" Datametrex (TSXV:DM) announces $700,000 renewal contract from LOTTE Data Communications

Datametrex AI (DM) has received a renewal service contract from LOTTE Data Communications for approximately C$700,000.
The Market Herald Video

" Callinex (TSXV:CNX) welcomes former HudBay CEO Peter R. Jones to the Technical Team

Callinex (CNX) has appointed mining engineer and entrepreneur Peter R. Jones to the company’s Technical Team. 

" AGF Management Limited (TSX:AGF.B) renews NCIB

AGF Management Limited (AGF.B) is renewing its normal course issuer bid of Class B non-voting shares.